Published Online
on February 2, 2004

A more recent version of this article appeared on February 24, 2004

This Article Full Text (PDF) All Versions of this Article: 109/7/874    most recent 01.CIR.0000112604.74713.35v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Sabatine, M. S. Articles by Braunwald, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID L-TYROSINE Medline Plus Health Information Blood Thinners Heart Attack Related Collections Cardiovascular Pharmacology Catheter-based coronary interventions: stents Acute coronary syndromes

Submitted on June 17, 2003
Revised on November 20, 2003
Accepted on November 21, 2003

Implications of Upstream Glycoprotein IIb/IIIa Inhibition and Coronary Artery Stenting in the Invasive Management of Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB Trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 Trial

Marc S. Sabatine MD, MPH^*, David A. Morrow MD, MPH, Robert P. Giugliano MD, MS, Sabina A. Murphy MPH, Laura A. Demopoulos MD, Peter M. DiBattiste MD, William S. Weintraub MD, Carolyn H. McCabe BS, Elliott M. Antman MD, Christopher P. Cannon MD, and Eugene Braunwald MD

From the TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital (M.S.S., D.A.M., R.P.G., S.A.M., C.H.M., E.M.A., C.P.C., E.B.), Boston, Mass; Merck & Co, West Point, Pa (L.A.D., P.M.D.); and Emory University, Atlanta, Ga (W.S.W.).

^* To whom correspondence should be addressed. E-mail: msabatine{at}partners.org.

Background--TIMI IIIB and TACTICS-TIMI 18 were 2 trials of an early invasive strategy in unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI) that were conducted nearly a decade apart but with virtually identical enrollment criteria and designs, except that upstream glycoprotein IIb/IIIa inhibition was mandated and coronary artery stenting was routinely used in TACTICS-TIMI 18. We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI.

Methods and Results--Patients were stratified on the basis of their TIMI risk score into low-, intermediate-, and high-risk categories. Within each risk category, the rates of clinical outcomes and the benefit of an early invasive strategy were compared. Compared with patients in TIMI IIIB and adjusting for baseline risk, patients in TACTICS-TIMI 18 had lower rates of death, MI, or rehospitalization for acute coronary syndromes (OR, 0.62; P<0.0001). Across both trials, the benefit of an early invasive strategy was significantly greater with increasing baseline risk: OR, 1.39 in low-risk, 0.80 in intermediate-risk, and 0.57 in high-risk patients (P0.004 for interactions). After adjustment for baseline risk, an early invasive strategy tended toward a more favorable result in TACTICS-TIMI 18 than in TIMI IIIB (OR, 0.79; 95% CI, 0.56 to 1.11).

Conclusions--Advances in the care of patients with UA/NSTEMI, including glycoprotein IIb/IIIa inhibition and stenting, were associated with lower rates of death, MI, and rehospitalization for acute coronary syndromes and a trend toward a greater benefit of an early invasive strategy.

Key words: angiography • inhibitors • risk factors • angina

This article has been cited by other articles:

				J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text]

				R. Glaser, H. A. Glick, H. C. Herrmann, and S. E. Kimmel The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes: A Cost-Effectiveness Analysis J. Am. Coll. Cardiol., February 7, 2006; 47(3): 529 - 537. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF]

				D. G. Katritsis and J. P.A. Ioannidis Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Circulation, June 7, 2005; 111(22): 2906 - 2912. [Abstract] [Full Text] [PDF]

				T. J. Gluckman, M. Sachdev, S. P. Schulman, and R. S. Blumenthal A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, January 19, 2005; 293(3): 349 - 357. [Abstract] [Full Text] [PDF]

				D. L. Bhatt, M. T. Roe, E. D. Peterson, Y. Li, A. Y. Chen, R. A. Harrington, A. B. Greenbaum, P. B. Berger, C. P. Cannon, D. J. Cohen, et al. Utilization of Early Invasive Management Strategies for High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative JAMA, November 3, 2004; 292(17): 2096 - 2104. [Abstract] [Full Text] [PDF]

				A. I. Larsen and K. Dickstein BNP in acute coronary syndromes: the heart expresses its suffering Eur. Heart J., August 1, 2004; 25(15): 1284 - 1286. [Full Text] [PDF]

				D. A. Morrow, E. M. Antman, S. A. Murphy, S. F. Assmann, R. P. Giugliano, C. P. Cannon, C. Michael Gibson, C. H. McCabe, H. V. Barron, F. Van de Werf, et al. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies Eur. Heart J., July 1, 2004; 25(13): 1139 - 1145. [Abstract] [Full Text] [PDF]